two neat structure papers in Nature, both using cryo-EM, very cool that you can capture the ligand-dependent G-coupled protein interactions too
— Paul D. Rennert (@PDRennert) June 21, 2018
adenosine/A2AR1/Gihttps://t.co/M6IHz9nujw
donitriptan/5-HT1BR/Go heterotrimershttps://t.co/j6hewJcI7S
Okay, I've seen enough, I'm calling it: #CRISPR has its killer app--turning white fat into brown fat. People w/more brown can burn off whatever they eat, cheesecake & all (almost). In vitro. Mice. I don't care; sign me up. https://t.co/9KWlfB0hsK
— sharon begley (@sxbegle) June 25, 2018
Wow. #CRISPR-ing the #brain: In an experimental model of #autism, nanoparticle delivery of genome editing achieved salutary effect on behavior. https://t.co/O1ikM1Mskd@natBME by @UTSA and @UCBerkeley @UCBerkeleyNews pic.twitter.com/go5YpvONiD
— Eric Topol (@EricTopol) June 25, 2018
Among men with nonmetastatic, castration-resistant #prostatecancer with a rapidly rising PSA level, enzalutamide treatment led to a clinically meaningful and significant 71% lower risk of metastasis or death than placebo. Learn more: https://t.co/4JdPTyKDA4 pic.twitter.com/7G2B5BkQUH
— NEJM (@NEJM) June 27, 2018
Check it out: great (free!) series on clinical trial stats!https://t.co/287Eqb2PH4https://t.co/W0dK3URpwOhttps://t.co/rBufAOv5aEhttps://t.co/5692NafVIx
— Frank David • Pharmagellan (@Frank_S_David) July 1, 2018
(Found 'em while writing forthcoming book on analyzing clinical trial data. Sign up for updates: https://t.co/S1gSabJIBQ) pic.twitter.com/qKnPFFt4WE
Our NGLY1 Deficiency disease modeling and drug screening paper is a Featured Article in this month’s #g3journal! @GeneticsGSA @gracescience @ngly1org https://t.co/q4lQQJULjR
— Perlara (@PerlaraPBC) July 2, 2018
In the APOLLO trial, patisiran, an RNAi therapeutic, improved multiple clinical manifestations of hereditary transthyretin amyloidosis. Full trial results: https://t.co/is1yB1uuIo pic.twitter.com/7K0TnwvgwQ
— NEJM (@NEJM) July 4, 2018
Inotersen, a modified oligonucleotide that targets TTR messenger RNA, improves the course of neurologic disease and quality of life in patients with hereditary transthyretin amyloidosis. Learn more: https://t.co/HBq3HRCjMC pic.twitter.com/zLl6QThCLt
— NEJM (@NEJM) July 4, 2018
Wow, this is pretty cool!#CRISPR-based reverse-engineered cancer cells with a 'kill switch' can home in on and destroy tumorshttps://t.co/74zN6PI2eAhttps://t.co/fRzB4ZXt0t pic.twitter.com/d3FFFAT0ip
— Andy Biotech (@AndyBiotech) July 12, 2018
Metastasis-free Survival—A New End Point in Prostate Cancer Trials. #FDAOncology perspective in @NEJM #prostatecancer #pcsm #OCEpubs https://t.co/qS6wjI3twh
— FDA Oncology (@FDAOncology) July 15, 2018
#CRISPR stocks getting rocked again...$EDIT -5%$CRSP -6%$NTLA -7%https://t.co/epeGNFxPLI
— Andy Biotech (@AndyBiotech) July 16, 2018
Here is the new @NatureBiotech paper about on-target mutagenesishttps://t.co/qKzBagXuha pic.twitter.com/nDP01LUWcY
A cure in the womb? Scientists are using #genetherapy and #CRISPR gene editing to treat genetic diseases in animal fetuses. A new @NatureMedicine paper treated a #Gaucher disease model in fetal mice. Read my story on the news and the field for @cenmag here https://t.co/thx59d350K
— Ryan Cross the Science Boss (@RLCscienceboss) July 16, 2018
The link between #diabetes and #cancer: the epidemiology is backed up by high glucose liability, epigenomic (methylome) mechanism, and metformin protective effect https://t.co/BfzpLava2H @nature pic.twitter.com/yWd8c10heT
— Eric Topol (@EricTopol) July 18, 2018
Another key paper identifies a possible druggable target for MEK resistance - any PP2A inhibitors out there? https://t.co/zcMPfMYK3p
— Sally Church □□□□□□□ (@MaverickNY) July 18, 2018